LB01 | VONOPRAZAN VS. PANTOPRAZOLE IN PREVENTION OF POST ENDOSCOPIC VARICEAL LIGATION ULCER/BLEEDING IN PORTAL HYPERTENSION: A RANDOMIZED CONTROLLED TRIAL

advanced age, male gender, total withdrawal time and endoscopist experience. Conclusion: The use of real ‐ time CADe during colonoscopies in endoscopists ‐ in ‐ training could increase the overall ADR, especially for small ‐ to ‐ medium size adenomas, in different levels of experience (ClinicalTrials.gov number: NCT04838951). Disclosure: This study received research grant

[1]  Susan M. Kilroy,et al.  Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab , 2022, Nature Communications.

[2]  M. Parkes,et al.  COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study , 2022, The Lancet Gastroenterology & Hepatology.

[3]  K. Iwanaga,et al.  Safety profile of vonoprazan compared with proton pump inhibitors: insight from a pharmacovigilance study. , 2020, Die Pharmazie.

[4]  F. Pace,et al.  Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non‐erosive reflux disease – efficacy of Esoxx, a hyaluronic acid–chondroitin sulphate based bioadhesive formulation , 2017, Alimentary pharmacology & therapeutics.

[5]  N. Hiramatsu,et al.  Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis , 2015, Alimentary pharmacology & therapeutics.

[6]  R. Hunt,et al.  Diagnosis and Management of Non-Erosive Reflux Disease – The Vevey NERD Consensus Group , 2009, Digestion.

[7]  D. Drossman,et al.  Rome III: The Functional Gastrointestinal Disorders , 2006 .

[8]  J. Dent,et al.  The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus , 2006, The American Journal of Gastroenterology.

[9]  R. D'Agostino,et al.  Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statistics , 2002, Statistics in medicine.

[10]  M. Camilleri,et al.  Functional gastroduodenal disorders , 1999, Gut.